1. Home
  2. CPZ vs ZNTL Comparison

CPZ vs ZNTL Comparison

Compare CPZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Long/Short Equity & Dynamic Income Trust

CPZ

Calamos Long/Short Equity & Dynamic Income Trust

HOLD

Current Price

$14.33

Market Cap

297.4M

Sector

Finance

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$2.71

Market Cap

156.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPZ
ZNTL
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
297.4M
156.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
CPZ
ZNTL
Price
$14.33
$2.71
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$6.60
AVG Volume (30 Days)
76.5K
695.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
47.87
EPS
N/A
N/A
Revenue
N/A
$67,425,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.24
$1.01
52 Week High
$16.82
$3.95

Technical Indicators

Market Signals
Indicator
CPZ
ZNTL
Relative Strength Index (RSI) 32.66 54.87
Support Level N/A $1.29
Resistance Level $15.13 $3.95
Average True Range (ATR) 0.21 0.22
MACD -0.05 0.04
Stochastic Oscillator 10.67 51.67

Price Performance

Historical Comparison
CPZ
ZNTL

About CPZ Calamos Long/Short Equity & Dynamic Income Trust

Calamos L/S Equity & Dynamic Inc Trust is a trust company that seeks to provide current income and risk-managed capital appreciation, with an investment objective to deliver total return through a combination of capital appreciation and current income. The Fund invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary, and others, and holds securities with a broad range of maturities, with the average term to maturity typically ranging from two to ten years. Managed assets represent the Fund's total assets, including any assets attributable to leverage that may be outstanding, minus total liabilities other than debt representing financial leverage.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: